DiCE Molecules: Funding, Investors & Team (Sep 2026)
Founded in 2013, DiCE Molecules develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its core technology was invented by Stanford Professor Pehr Harbury, a 2005 recipient of the Macarthur "genius" award. In addition to Professor Harbury, the founding team includes Dr. Phil Patten, formerly of Maxygen, Achaogen, and DuPont, who serves as our Chief Scientific Officer; Dr. John Bedbrook, a renowned serial entrepreneur in the agricultural biotechnology space, who is the Chairman of the DiCE Board of Directors; and Dr. Kevin Judice, who served various leadership roles at Genentech, Theravance, and Achaogen prior to joining DiCE as CEO.
DiCE Molecules has raised $140M across 2 funding rounds on record, the most recent a Series C of $60.0M announced in Aug 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
DiCE Molecules Company Profile and Key Stats
Latest funding round on record: Aug 2021.
DiCE Molecules Funding Rounds
DiCE Molecules raised $80.0M in a Series C announced in Jan 2021.
7 months later, a Series C of $60.0M was announced in Aug 2021.
DiCE Molecules Founders and Leadership Team
Contact details for the DiCE Molecules team: 1 of 1 has an email address on file.
Start 14-day free trial →DiCE Molecules Funding Compared to Other Biotechnology Startups
DiCE Molecules' latest round of $60.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like DiCE Molecules in Biotechnology and Menlo Park
Companies Similar to DiCE Molecules
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
DiCE Molecules Funding FAQs
What does DiCE Molecules do?
Founded in 2013, DiCE Molecules develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its core technology was invented by Stanford Professor Pehr Harbury, a 2005 recipient of the Macarthur "genius" award. In addition to Professor Harbury, the founding team includes Dr. Phil Patten, formerly of Maxygen, Achaogen, and DuPont, who serves as our Chief Scientific Officer; Dr. John Bedbrook, a renowned serial entrepreneur in the agricultural biotechnology space, who is the Chairman of the DiCE Board of Directors; and Dr. Kevin Judice, who served various leadership roles at Genentech, Theravance, and Achaogen prior to joining DiCE as CEO.
How much funding has DiCE Molecules raised?
DiCE Molecules has raised $140M across 2 rounds on record. The most recent is a Series C of $60.0M announced in Aug 2021.
When did DiCE Molecules last raise funding?
DiCE Molecules' most recent funding round on record is a Series C of $60.0M, announced in Aug 2021.
Who is the CEO of DiCE Molecules?
Kevin Judice is listed as CEO at DiCE Molecules.
Where is DiCE Molecules headquartered?
DiCE Molecules is based in Menlo Park, California, United States.
How many employees does DiCE Molecules have?
DiCE Molecules is in the 11-50 employee band.
How does DiCE Molecules' funding compare to other Biotechnology startups?
DiCE Molecules' latest round of $60.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's DiCE Molecules Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for DiCE Molecules is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.